Biotech Daily

Thursday July 23, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH EVEN: PRESCIENT UP 20.5%; PROTEOMICS DOWN 8%**

*** POLYNOVO UNAUDITED REVENUE UP 18% TO $150m**

*** ALCIDION RECEIPTS UP 10% TO $56m**

*** ADHERIS RECEIPTS DOWN 62% TO $34m**

*** GENETIC SIGNATURES RECEIPTS DOWN 7% TO $17m**

*** ATOMO RECEIPTS DOWN 6% TO $4.5m**

*** PRINCE CHARLES HOSPITAL PEXA LUNG DISEASE DIAGNOSTIC**

*** CLINUVEL UP-TO 20% STAFF CUTS; US RELOCATION**

*** TISSUE REPAIR TO DELIST FROM ASX**

*** ARTRYA: NORTHEAST GEORGIA HEALTH STARTS SALIX**

*** NEXSEN OPENS HONG KONG R&D FACILITY**

*** VITRAFY, HOXWORTH FOR RED BLOOD CELL CRYO-PRESERVATION**

*** DIMERIX WINS US DMX-652 PATENT**

MARKET REPORT

The Australian stock market was up 0.18 percent on Thursday July 23, 2026, with the ASX200 up 16.0 points to 8,839.0 points. Fourteen of the Biotech Daily Top 40 companies were up, 14 fell, 10 traded unchanged and two were untraded. All four Big Caps fell.

Prescient was the best, up 1.6 cents or 20.5 percent to 9.4 cents, with 3.8 million shares traded. Syntara rose 14.3 percent; Imricor was up 10.6 percent; Clarity climbed 9.4 percent; Artrya was up 6.3 percent; Aroa and Medical Developments rose four percent or more; Micro-X and Optiscan were up more than three percent; Actinogen, Cyclopharm, Lumos and Telix rose more than two percent; with Clinuvel up by 0.7 percent.

Proteomics led the falls, down 1.5 cents or 8.1 percent to 17 cents, with 976,064 shares traded. Pro Medicus lost 6.5 percent; Curvebeam was down 5.6 percent; 4D Medical, Avita, Dimerix and Neuren fell four percent or more; Emvision, Polynovo and Saluda shed more than two percent; CSL, EBR and Imugene were down more than one percent; with Cochlear, Mesoblast, Nanosonics, Orthocell and Resmed down by less than one percent.

POLYNOVO

Polynovo says unaudited revenue for the year to June 30, 2026 was up 17.9 percent to $150.0 million, compared to the prior corresponding period.
Last year, Polynovo said revenue for the year to June 30, rose 23.3 percent to $127.2 million, with net profit after tax up 151.2 percent to $13.2 million (BD: Aug 25, 2025).
Today, the company said $125.8 million came from sales of its Novosorb biodegradable wound treatment, up 12.4 percent on the prior year, with US Biomedical Advanced Research and Development Authority revenue down 38.4 percent to $5.3 million.
Polynovo chair Leon Hoare said the “revenue result was very solid, reflecting a broadening of both the customer and indication base; and as anticipated, both operating and free cash flow were strong”.
The company said it had a positive cash flow of $24.0 million for the year, including $3.5 million from its research and development laboratory insurance claim, with cash and cash equivalents of $35.4 million at June 30, 2026 compared to $33.5 million at June 30, 2025.
Polynovo fell 2.5 cents or 2.6 percent to 92.5 cents with 9.3 million shares traded.

ALCIDION GROUP

Alcidion says receipts from customers for the year to June 30, 2026 were up 10.2 percent to a record $56,060,000, compared to the previous corresponding period.
Alcidion said customer receipts from sales contracts of its Miya Precision patient management software products and services as well as the acquired Telstra Health’s Kyra flow products for the three months to June 30, 2026 rose 9.8 percent to $24,555,000, compared to the prior corresponding period.
The company said it expected revenue for the year to be about $51.6 million, subject to audit, up 27 percent on the previous year, with earnings before interest, taxation, depreciation and amortization (Ebitda) to be more than $5.0 million.
Adheris said it was $7,734,000 cash-flow positive for the three months, with cash and equivalents of $20,642,000 at June 30, 2026 compared to $17,697,000 the prior year.
Alcidion was unchanged at 9.2 cents with 5.3 million shares traded.

ADHERIS (FORMERLY MEDADVISOR)

Adheris says receipts from customers for the year to June 30, 2026 were down 61.9 percent to $33,694,000, compared to the previous corresponding period.
Last year, the then Medadvisor said it had an agreement to sell its Australia and New Zealand business to Brisbane’s Jonas Software Australia Pty Ltd and had recorded this business as discontinued operations for the year to June 30, 2025 (BD: Jul 7, 2025).
The company said revenue was down due to “lower customer renewal rates during the prior pharma budgetary period, and lower bookings in [the six months to December 31, 2025] comparted to the prior year, which impacted revenue in the current period”.
Adheris managing-director John Ciccio said the result reflected “sustained cost discipline, strengthened customer relationships, improved revenue pull-through, and out-of-cycle contract wins during a traditionally quiet sales period”.
Today, the company said customer receipts from contracts for its patient medication management platform with pharmacies in the three months to June 30, 2026 fell 52.2 percent to $9,317,000, compared to the prior corresponding period.
Adheris said it had a three-month positive cash flow of $227,000, with cash and cash equivalents of $9,504,000 at June 30, 2026 compared to $12,552,000 at June 30, 2025.
Adheris was up 0.1 cents or 5.9 percent to 1.8 cents with 2.3 million shares traded.

GENETIC SIGNATURES

Genetic Signatures says receipts from customers for the year to June 30, 2026 fell 7.4 percent to $16,817,000, compared to the previous corresponding period.
Genetic Signatures said receipts for the three months to June 30, 2026 from sales of its Easyscreen gastro-intestinal and respiratory infection diagnostics were up 17.15 percent to $2,990,000, compared to the prior corresponding period.
The company said it had a three-month cash burn of $3,382,000, with cash and cash equivalents of $22,066,000 at June 30, 2026 compared to $30,873,000 at June 30, 2025.
Genetic Signatures fell 0.2 cents or 3.3 percent to 5.9 cents.

ATOMO DIAGNOSTICS

Atomo says receipts from customers for the year to June 30, 2026 fell 6.3 percent to $4,456,000, compared to the previous corresponding period.
Atomo said receipts from sales of its HIV self-tests, the Lumos Febridx tests for respiratory diseases and the Pascal blood-based Burnet Institute syphilis test for the three months to June 30, 2025 fell 13.1 percent to $904,000.
Atomo said it had a $1,614,000 cash burn for the three months, with cash and equivalents of $3,709,000 at June 30, 2026 compared to $3,220,000 at June 30, 2025.
Atomo was unchanged at 1.7 cents with 2.8 million shares traded.

PRINCE CHARLES HOSPITAL

Prince Charles Hospital says its “world-first research” is studying whether Pexa, exhaled particles in air, can diagnose silicosis lung disease before irreversible damage.
Brisbane’s Prince Charles Hospital said using “Australia’s first dedicated Pexa” machine, researchers could capture “microscopic particles naturally exhaled from the very deepest part of the lung through a simple breathing test”.
The Hospital said “the proteins expressed in these particles could reveal the earliest biological changes associated with silicosis, long before the disease can be detected through existing testing”.
The Prince Charles Hospital said silicosis was associated with construction, mining, tunnelling and stonemasonry and was an “incurable chronic lung disease caused by breathing in fine silica dust” and was one of the most serious occupational lung diseases”.
The Hospital said despite protections and increased awareness, silicosis was “frequently diagnosed only after significant and irreversible scarring has developed within the lungs”.
The Prince Charles Hospital said Pexa was first introduced to Australia in 2024, with industry investment to enable the purchase of Australia's first dedicated Pexa machine, ensuring ongoing access to the technology and allowing the research program to expand.
The Hospital said the technology was “enabling world-first research comparing breath samples, bronchoalveolar lavage and blood-based biomarkers, with researchers analyzing samples from both silicosis patients and healthy volunteers to identify early disease signatures and develop future non-invasive screening tools”.
The Prince Charles Hospital said CPB Contractors had provided $300,000 over three years to fund the research, with additional support from the Tradie Health Institute initiative to develop portable, on-site lung screening to allow “high-risk workers to be monitored before symptoms appear”.
Queensland Lung Transplant Services head of research and Prince Charles Hospital physician Prof Dan Chambers said the technology was “a major shift in what is possible for workers at risk … [which] could allow us to identify disease much earlier”.

CLINUVEL PHARMACEUTICALS

Clinuvel says it will reduce its workforce by up-to 20 percent and relocate its corporate headquarters to the US to focus on commercialization, effective from January 1, 2027.
On Tuesday, Clinuvel fell 25 US cents or 3.3 percent to $US7.40 ($A10.56) per American depository shares (ADS) following its uplift to a Level II Nasdaq listing (BD: Jul 21, 2026).
Today, the company said it would relocate its corporate headquarters and key functions to the US, “to strengthen regulatory engagement and commercial partnerships”.
Clinuvel said it was “reducing its global workforce by approximately 10 percent to 20 percent and relocating select functions to the US”.
The company said the reduction was “a necessary realignment of operating expenditure with current revenue generation and near-term clinical and commercial priorities”.
Clinuvel said operational resources would “be pivoted exclusively toward the US pharmaceutical pipeline and commercial strategy”; and the US was more than “40 percent of the global pharmaceutical market by value and is the primary ecosystem for premium pricing, regulatory advancement, and [merger and acquisition] activity”.
The company said the restructuring was “a prerequisite to unlocking deeper, more liquid capital pools in the US” and more than 66 percent of its shareholder register was held by foreign investors, with the majority in North America and Europe.
The company said its late-stage programs, particularly in vitiligo, were “primarily targeted at the US patient population”.
Clinuvel said relocating the base and operational headquarter to the US positioned it “to access distribution, and potential partnership infrastructure”.
Clinuvel chief operating officer Lachlan Hay said the company had “long contemplated a US listing and concluded that the company has reached a stage of maturity sufficient to attract the attention of US investors”.
“Since our future operations will be centred in the US, we are now positioning the business functions for these next phases,” Mr Hay said.
“This restructuring positions the company for a future of growth and will benefit shareholders, patients, and stakeholders over the long-term,” Mr Hay said.
Clinuvel was up seven cents or 0.7 percent to $9.95.

TISSUE REPAIR

Tissue Repair says it has formally applied to the ASX requesting its removal from the official list in accordance with Listing Rule 17.11 as well as conduct a share buy-back.
Tissue Repair said the reasons for its delisting included limited liquidity and utility of listing, concentrated shareholder structure, a significant number of small shareholders, cost and administrative burden, as well as strategic flexibility.
The company said its delisting was subject to shareholder approval at an extraordinary general meeting.
Tissue Repair said it would conduct an up-to $1,000,000 off-market share buy-back at 13 cents a share “to provide shareholders with a structure and orderly opportunity to realize value for their shares”.
The company said the buy-back price was an 18.2 percent premium to the 90-day volume weighted average price and that the buy-back would be funded by existing cash reserves.
Tissue Repair said it would also conduct an unmarketable parcel sale facility, with the shareholder meeting expected on August 31, 2026, the buy-back offer to open on September 2 and close on September 30 as well as the unmarketable parcel facility to be completed on October 5, 2026.
Tissue Repair fell 1.5 cents or 15.8 percent to eight cents with 1.5 million shares traded.

ARTRYA

Artrya says its Salix platform has been implemented within the Northeast Georgia Health System (NGHS) with first patient scans processed and revenue generated.

Last year, Artrya said it had US Food and Drug Administration 510(k) clearance for its Salix coronary anatomy platform and Salix coronary plaque module for detecting high-risk plaque, an indicator of heart disease; and it had a three-year, minimum $300,000 agreement with Atlanta's Northeast Georgia Health System for the use of its Salix coronary anatomy platform (BD: Mar 28, Aug 21, Dec 8, 2025).

Today, Artrya said the Salix coronary anatomy and coronary plaque modules were in use "in the first of NGHS' five hospitals and outpatient facilities with the Salix roll-out to be expanded to all other sites in the near term".

The company said with routine use of Salix, it would "deliver both monthly subscription fees and fee-per-scan revenue on Salix plaque assessments".

Artrya said it was "on-track for all three US foundation partners to be commercial in the near future".

The company said its Salix coronary flow module, once FDA cleared, would "then be activated for clinical use and generate fee-per-scan revenues as well".

Artrya chief executive officer John Konstantopoulos said the team had "worked incredibly hard to successfully integrate Salix and train the clinical team at NGHS over these last few months".

"We are all excited to see the Georgia Heart Institute's cardiologists using Salix on real patients across their first site and build their confidence in the product," Mr Konstantopoulos said. "We're already seeing strong clinical engagement that should underpin growing adoption, and we aim to have Cone Health online in the near future."

Artrya was up 34 cents or 6.3 percent to $5.75 with 613,890 shares traded.

NEXSEN

Nexsen says it has opened a research and development facility in Hong Kong to advance the clinical validation and commercialization of its diagnostics for various indications.

Nexsen said the laboratory complemented its existing Australian operations and would support the ongoing development of its tests for group B Streptococcus, acute kidney injury, chronic kidney disease, bovine mastitis as well as biosecurity and food safety.

The company said the facility was supported by a $HK6 million ($A1 million) Ignite grant and provided "a physical base for Nexsen's growing network of university, clinical and healthcare partnerships in Hong Kong, enabling closer collaboration across research, product development and clinical validation".

Nexsen said the laboratory would be operated by a local team of full-time researchers, opening permanent research and development capability in Hong Kong and strengthening its ability to manage regional research programs, clinical collaborations and product development activities.

Nexsen managing-director Mark Muzzin said the facility was "an important step in building Nexsen's presence across Asia and expanding the reach of our rapid diagnostics".

"By creating a dedicated local [research and development] base, we can work more closely with our university, clinical and healthcare partners, bringing together the expertise, patient access and translational capability already established through Nexsen Hong Kong," Mr Muzzin said. "This positions us to advance our existing portfolio, develop new programs in traumatic brain injury and neonatal sepsis, and move innovation closer to the populations, regulators and healthcare markets we intend to serve."

Nexsen fell 1.5 cents or 5.1 percent to 28 cents.

VITRAFY LIFE SCIENCES

Vitrafy says with the Cincinnati, Ohio-based Hoxworth Blood Center it will configure its next-generation cryo-preservation systems for red blood cell cryo-preservation.

Vitrafy said the Hoxworth Blood Center, University of Cincinnati, was founded in 1938 and was one of the oldest blood centres in the US, responsible for collecting about one percent of total units of blood in the US in 2024.

The company said the partnership would work to address the “emerging threat to existing red blood cell cryo-preservation workflows created by the discontinuation of critical legacy technology from 2027”.

Vitrafy said it and Hoxworth would “each contribute resources and in-kind support toward delivering a solution to this emerging threat” and that the agreement was “not expected to generate revenue for the company”.

The company said it would initially place one cryo-preservation freezing and software package at Hoxworth by the end of 2026, and expected the partnership “to support broader engagement with market participants and government stakeholders toward a unified industry response to the red blood cell preservation issue”.

Vitrafy was up 39 cents or 13.9 percent to $3.20.

DIMERIX

Dimerix says the US Patent and Trademark Office has granted a patent protecting its recently acquired DMX-652 for acute kidney injury associated with cardiac surgery.

Last week, Dimerix said it would pay up-to $US292 million ($A418 million) plus royalties for the Cambridge, England-based Mission Therapeutics’ DMX-652 for acute kidney injury (BD: Jul 17, 2026).

Today, the company said the patent, titled ‘N-cyanopyrrolidines with activity as USP30 inhibitors’ would protect its intellectual property until April 11, 2043.

Dimerix company said the patent covered composition of matter-type claims for DMX-652, with a divisional application also filed to pursue additional claims covering.

Dimerix fell one cent or four percent to 24 cents with 3.4 million shares traded.